Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, combined with osimertinib, as first-line therapy or after progression on osimertinib in non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Cappuzzo, F. [1 ]
Moreno Garcia, V. [2 ]
Ou, S-H. I. [3 ]
Brandao, M. [4 ]
Sanmamed, M. F. [5 ]
Helissey, C. [6 ]
Wislez, M. [7 ]
Call, J. A. [8 ]
Grisanti, S. [9 ]
Johnson, M. L. [10 ]
Boni, V. [11 ]
Jamme, P. [12 ]
Monnet, I. [13 ]
Siena, S. [14 ]
Yan, C. [15 ]
Barasa, B. [16 ]
Richard, B. [17 ]
Joe, A. K. [18 ]
Laus, G. [18 ]
Felip, E. [19 ]
机构：
[1] IRCCS Ist Nazl Tumori Regina Elena IRE, Med Oncol, Rome, Italy
[2] Hosp Univ Fdn Jimenez Diaz, START Madrid FJD Early Phase Clin Trials Unit, Madrid, Spain
[3] UCI Hlth Chao Family Comprehens Canc Ctr, Med Dept, Orange, CA USA
[4] Inst Jules Bordet, Med Oncol Dept, Brussels, Belgium
[5] Clin Univ Navarra, Oncol Dept, Pamplona, Spain
[6] Begin Mil Teaching Hosp, Clin Res Unit, St Mande, France
[7] Hop Cochin AP HP, Paris, France
[8] South Texas Accelerated Res Therapeut START, Phase Trials, San Antonio, TX USA
[9] Univ Brescia, Med Oncol Dept, Brescia, Italy
[10] Sarah Cannon Res Inst, Lung Canc Res, Canc Ctr, Nashville, TN USA
[11] Hosp Univ Quironsalud Madrid, Oncol Dept, Pozuelo De Alarcon, Spain
[12] Ctr Hosp Reg Univ Lille, CHU Lille, Haut France, Lille, France
[13] CHI Creteil, Creteil, France
[14] Univ Milano Statale, UNIMI, Hematooncol Dept, Milan, Italy
[15] Merus NV, Biostat, Utrecht, Netherlands
[16] Merus NV, Translat Res, Utrecht, Netherlands
[17] Merus NV, Clin Operat, Utrecht, Netherlands
[18] Merus NV, Clin Dev, Utrecht, Netherlands
[19] Vall Hebron Univ Hosp, Lung Canc Unit, Med Oncol Serv, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.595
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
516MO
引用
收藏
页码：S1671 / S1671
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of MCLA-129, an EGFR/c-MET bispecific antibody, in advanced non-small cell lung cancer (NSCLC)
    Wang, Jie
    Zhong, Jia
    Wu, Lin
    Chen, Bolin
    Wang, Zhe-Hai
    Yao, Yu
    Dong, Xiaorong
    Li, Wei
    Ren, Xiubao
    Hou, Xiaoming
    Zang, Ai-min
    Qu, Xiujuan
    Zhang, Guojun
    Wang, Yongsheng
    Bai, Yuansong
    Liu, Linlin
    Yu, Guohua
    Chen, Xingwu
    Ding, Lieming
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in head and neck squamous cell cancer (HNSCC)
    Bossi, P.
    Minuti, G.
    Brana, I.
    Garcia, V. Moreno
    Boni, V.
    Jamme, P.
    Call, J. A.
    Yan, C.
    Barasa, B.
    Doze, P.
    Joe, A. K.
    Laus, G.
    Daste, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S1610 - S1611
  • [3] Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in non-small-cell lung cancer (NSCLC) with c-METexon 14 skipping mutations (METex14).
    Brandao, Mariana da Rocha Almeida
    Zugazagoitia, Jon
    Dingemans, Anne-Marie C.
    Duruisseaux, Michael
    Parent, Pauline
    Juan-Vidal, Oscar
    Spira, Alexander I.
    Vicier, Cecile
    Zalcman, Gerard
    Barasa, Ben
    Yan, Chris
    Doze, Petra
    Joe, Andrew K.
    Laus, Gianluca
    Felip, Enriqueta
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Mechanism of action of MCLA-129, a bispecific antibody that targets EGFR and c-MET and impairs growth of EGFR exon 20 insertion mutant non-small cell lung cancer
    de Gorter, David J.
    O'Connor, Marie
    Deshiere, Alexandre
    van Rosmalen, Martijn
    Fatrai, Szabolcs
    van Bueren, Jeroen Lammerts
    Geuijen, Cecile A.
    CANCER RESEARCH, 2022, 82 (12)
  • [5] Inhalable Anti-EGFR Antibody-Conjugated Osimertinib Liposomes for Non-Small Cell Lung Cancer
    Daram, Apoorva
    Sawant, Shruti S.
    Mehta, Dhwani A.
    Sanhueza, Carlos A.
    Kunda, Nitesh K.
    PHARMACEUTICS, 2024, 16 (11)
  • [6] Efficacy and safety study of osimertinib in advanced non-small cell lung cancer (NSCLC) with EGFR mutation
    Garcia Samblas, Victoria
    Fernandez Madrigal, Laura
    Rodriguez Garces, Maria Yeray
    Inoriza, Angel
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Osimertinib beyond Progression in Patients with EGFR Mutated Non-small Cell Lung Cancer (NSCLC) Receiving Frontline Osimertinib
    Benyounes, A.
    Cohen, A.
    Rossi, S. Diamond
    Cannon, T.
    Yacur, M.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S657 - S657
  • [8] Concurrent osimertinib plus gefitinib for first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC).
    Rotow, Julia K.
    Costa, Daniel Botelho
    Paweletz, Cloud P.
    Awad, Mark M.
    Marcoux, Paul
    Rangachari, Deepa
    Barbie, David Allen
    Sands, Jacob
    Cheng, Michael L.
    Johnson, Bruce E.
    Oxnard, Geoffrey R.
    Jackman, David Michael
    Kwiatkowski, David J.
    Kehl, Kenneth L.
    Izdebski, Monika D.
    Lau, Christie J.
    Vasquez, Kevin A.
    Janne, Pasi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] First-line osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer
    Jeong, Byeong-Ho
    Um, Sang-Won
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (03)
  • [10] Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small Cell Lung Cancer after Progression following First-Line EGFR TKI Therapy
    Wu, Bin
    Gu, Xiaohua
    Zhang, Qiang
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (02) : 184 - 193
12345